Bnp Paribas Arbitrage Sa Has Lowered By $15.39 Billion Its Westlake Chem (WLK) Stake; Valley National Advisers Lifted Its Cvs Health (CVS) Stake

January 18, 2018 - By Nellie Frank

Valley National Advisers Inc increased Cvs Health Corp (CVS) stake by 481.93% reported in 2017Q3 SEC filing. Valley National Advisers Inc acquired 12,747 shares as Cvs Health Corp (CVS)’s stock declined 4.23%. The Valley National Advisers Inc holds 15,392 shares with $1.25 million value, up from 2,645 last quarter. Cvs Health Corp now has $80.54 billion valuation. The stock increased 0.08% or $0.06 during the last trading session, reaching $79.5. About 7.45 million shares traded. CVS Health Corporation (NYSE:CVS) has declined 24.40% since January 18, 2017 and is downtrending. It has underperformed by 41.10% the S&P500.

Bnp Paribas Arbitrage Sa decreased Westlake Chem Corp (WLK) stake by 97.22% reported in 2017Q3 SEC filing. Bnp Paribas Arbitrage Sa sold 185,279 shares as Westlake Chem Corp (WLK)’s stock rose 1.98%. The Bnp Paribas Arbitrage Sa holds 5,302 shares with $440.54M value, down from 190,581 last quarter. Westlake Chem Corp now has $14.04 billion valuation. The stock decreased 1.48% or $1.63 during the last trading session, reaching $108.77. About 1.33 million shares traded or 60.63% up from the average. Westlake Chemical Corporation (NYSE:WLK) has risen 45.05% since January 18, 2017 and is uptrending. It has outperformed by 28.35% the S&P500.

Among 25 analysts covering CVS Health (NYSE:CVS), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. CVS Health had 65 analyst reports since July 22, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Thursday, August 20 by Deutsche Bank. Jefferies maintained CVS Health Corporation (NYSE:CVS) on Tuesday, November 7 with “Hold” rating. The stock has “Hold” rating by Jefferies on Monday, December 12. The rating was downgraded by Wolfe Research on Monday, August 14 to “Peer Perform”. The company was maintained on Monday, November 2 by S&P Research. The company was maintained on Friday, September 15 by Jefferies. The firm has “Neutral” rating given on Monday, February 6 by Atlantic Securities. Robert W. Baird maintained it with “Hold” rating and $77.0 target in Monday, September 25 report. As per Monday, January 8, the company rating was maintained by Leerink Swann. The rating was maintained by Oppenheimer with “Outperform” on Friday, August 28.

Investors sentiment decreased to 0.88 in 2017 Q3. Its down 0.04, from 0.92 in 2017Q2. It fall, as 60 investors sold CVS shares while 571 reduced holdings. 88 funds opened positions while 466 raised stakes. 801.45 million shares or 0.31% less from 803.96 million shares in 2017Q2 were reported. Silvercrest Asset Management Group Inc Ltd owns 556,895 shares for 0.45% of their portfolio. Baystate Wealth Ltd Liability reported 1,444 shares. Manufacturers Life Insurance The has 0.19% invested in CVS Health Corporation (NYSE:CVS). Sol Cap Mgmt invested 0.21% in CVS Health Corporation (NYSE:CVS). Cohen Steers Inc holds 0.04% of its portfolio in CVS Health Corporation (NYSE:CVS) for 191,794 shares. Proshare Ltd Com holds 0.11% or 142,207 shares in its portfolio. Los Angeles Management And Equity Research holds 344,282 shares or 0.16% of its portfolio. Magellan Asset Mgmt stated it has 917 shares. Thomaspartners Inc holds 1.66% or 2.55M shares. Northeast Investment Mngmt reported 292,459 shares stake. Cacti Asset Mgmt Ltd Llc invested in 576,253 shares. Cypress Cap Gru owns 17,918 shares or 0.31% of their US portfolio. 48,255 were accumulated by Kj Harrison Partners Inc. Van Eck Assoc has 442,156 shares for 0.18% of their portfolio. 337,816 were accumulated by Commonwealth Equity Serv.

Since August 16, 2017, it had 0 insider purchases, and 7 insider sales for $58.32 million activity. Foulkes Helena also sold $3.22 million worth of CVS Health Corporation (NYSE:CVS) shares. $199,050 worth of CVS Health Corporation (NYSE:CVS) was sold by SWIFT RICHARD J. 85,743 shares were sold by Roberts Jonathan C, worth $7.13M. Moriarty Thomas M also sold $7.19 million worth of CVS Health Corporation (NYSE:CVS) on Monday, September 11. 237,078 shares were sold by Denton David M, worth $18.88M on Monday, September 11. $20.03M worth of CVS Health Corporation (NYSE:CVS) was sold by MERLO LARRY J.

Since August 15, 2017, it had 0 buys, and 1 sale for $968,620 activity. Bender Mark Steven sold 13,794 shares worth $968,620.

Investors sentiment increased to 1.38 in 2017 Q3. Its up 0.23, from 1.15 in 2017Q2. It is positive, as 21 investors sold WLK shares while 61 reduced holdings. 55 funds opened positions while 58 raised stakes. 37.12 million shares or 5.60% less from 39.33 million shares in 2017Q2 were reported. Symphony Asset Management Ltd stated it has 0.34% of its portfolio in Westlake Chemical Corporation (NYSE:WLK). Raymond James & Associates has 3,220 shares. State Board Of Administration Of Florida Retirement System has invested 0.01% of its portfolio in Westlake Chemical Corporation (NYSE:WLK). Credit Suisse Ag invested in 0.01% or 145,023 shares. Marvin And Palmer Assoc has invested 2.98% in Westlake Chemical Corporation (NYSE:WLK). Moreover, Bancorpsouth Inc has 0.05% invested in Westlake Chemical Corporation (NYSE:WLK) for 6,354 shares. Hl Serv Ltd Limited Liability Company reported 2,524 shares. Alpine Glob Lc reported 0.11% of its portfolio in Westlake Chemical Corporation (NYSE:WLK). Dreman Value Mngmt L L C has 113 shares. Moreover, Prudential Fin has 0.01% invested in Westlake Chemical Corporation (NYSE:WLK). 40,466 are held by Jennison Associate Ltd Liability. Quantitative Management Limited Liability Corp invested 0.17% of its portfolio in Westlake Chemical Corporation (NYSE:WLK). 4,437 are owned by Jaffetilchin Inv Partners Limited Liability Com. 13,044 were accumulated by Clinton Gru Incorporated. Highbridge Capital Mngmt Limited has 0.25% invested in Westlake Chemical Corporation (NYSE:WLK).

Among 18 analysts covering Westlake Chemical (NYSE:WLK), 12 have Buy rating, 2 Sell and 4 Hold. Therefore 67% are positive. Westlake Chemical had 51 analyst reports since July 24, 2015 according to SRatingsIntel. JP Morgan maintained the stock with “Overweight” rating in Tuesday, August 16 report. The stock of Westlake Chemical Corporation (NYSE:WLK) has “Buy” rating given on Wednesday, November 8 by Nomura. The stock of Westlake Chemical Corporation (NYSE:WLK) earned “Neutral” rating by Bank of America on Wednesday, November 8. The stock of Westlake Chemical Corporation (NYSE:WLK) earned “Hold” rating by Vertical Research on Wednesday, January 3. The rating was downgraded by Goldman Sachs to “Neutral” on Monday, August 10. The stock of Westlake Chemical Corporation (NYSE:WLK) has “Buy” rating given on Thursday, December 7 by Wells Fargo. Citigroup maintained Westlake Chemical Corporation (NYSE:WLK) on Tuesday, October 24 with “Buy” rating. The firm has “Underperform” rating by Bank of America given on Tuesday, January 16. The company was upgraded on Wednesday, June 15 by SunTrust. Nomura initiated the shares of WLK in report on Friday, July 24 with “Neutral” rating.

Analysts await Westlake Chemical Corporation (NYSE:WLK) to report earnings on February, 20. They expect $1.64 earnings per share, up 88.51% or $0.77 from last year’s $0.87 per share. WLK’s profit will be $211.74 million for 16.58 P/E if the $1.64 EPS becomes a reality. After $1.65 actual earnings per share reported by Westlake Chemical Corporation for the previous quarter, Wall Street now forecasts -0.61% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

Twitter Auto Publish Powered By : XYZScripts.com